scholarly journals Effect of angiotensin II receptor antagonists on left ventricular hypertrophy, vascular elasticity, and lipid and carbohydrate metabolic parameters in metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 27-33
Author(s):  
S V Nedogoda ◽  
A S Salasyuk ◽  
T A Chalyabi ◽  
I N Barykina ◽  
D A Pocheptsov ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Left Ventricular ◽  
Metabolic Parameters ◽  
Antihypertensive Activity ◽  
Angiotensin Ii Receptor ◽  
Anthropometric Parameters ◽  
Parallel Group ◽  
Obesity Therapy ◽  
Positive Effect

Aim: to evaluate the antihypertensive efficacy and effects of telmisartan and losartan on metabolic parameters in patients with arterial hypertension and metabolic syndrome. Subjects and methods. A blind randomized, controlled, parallel group comparative (telmisartan versus losartan for 24 weeks) trial enrolled 60 patients with arterial hypertension and metabolic syndrome. Results. Significant differences were found in favor of telmisartan in antihypertensive activity, cardio-, angio-, and nephroprotection and ability to improve lipid and carbohydrate metabolic parameters. Only did telmisartan reduce the manifestations of insulin resistance and hyperleptinemia in patients with hypertension and obesity. Therapy with telmisartan versus losartan exerted a pronounced positive effect on anthropometric parameters and fat deposition rate. The drugs were found to be well tolerated and to cause no adverse reactions in both groups.

scholarly journals Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction

2013 ◽  
Vol 4 (2) ◽  
pp. 57-66
Author(s):  
S. V Nedogoda ◽  
A. S Salasyuk ◽  
I. N Barykina ◽  
A. A Ledyaeva ◽  
V. V Tsoma ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Erectile Dysfunction ◽  
Metabolic Parameters ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Group Evaluation ◽  
Parallel Group ◽  
Quality Of Life Indicators ◽  
Negative Effect ◽  
Positive Effect

Objective: to evaluate the antihypertensive efficacy and effect of nebivolol and valsartan on metabolic parameters and erective function in patients with hypertension, metabolic syndrome, and erectile dysfunction. Subjects and methods. A 12-week randomized, blind, controlled, parallel-group, comparative (nebivolol versus valsartan) trial enrolled 40 patients with hypertension, metabolic syndrome, and erectile dysfunction. Results. There were no significant differences between the drugs in their antihypertensive efficiency. Nebivolol exerted a more pronounced positive effect on cardioand angioprotection and lipid and carbohydrate metabolic parameters. It had no negative effect on metabolic parameters. Therapy with nebivolol versus valsartan produced a pronounced positive effect on blood androgen levels and erectile function. Moreover, the quality-of-life indicators also showed a significant improvement in the nebivolol group. Evaluation of the tolerability and adverse reactions of the drugs demonstrated no side effects in both groups.

scholarly journals Changes of morphofunctional state of cardiovascular system in adolescents with metabolic syndrome manifestations

2021 ◽  
Vol 12 (1) ◽  
pp. 21-30
Author(s):  
Natalya V. Gonchar ◽  
Аnzhela А. Аvakyan ◽  
Svetlana N. Chuprova ◽  
Nikolay V. Slizovskiy
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Cardiovascular System ◽  
Autonomic Dysfunction ◽  
Ventricular Remodeling ◽  
Left Ventricular Remodeling ◽  
Holter Monitoring ◽  
Left Ventricular ◽  
Diagnostic Methods ◽  
Group 2

The results of investigation of features of morphofunctional state of cardiovascular system in adolescents with manifestations of metabolic syndrome depending on presence of hyperuricemia are presented. In the cardiorheumatology department of the hospital, 34 adolescent patients were observed. Criteria for inclusion in the study: the presence of increased blood pressure levels, increased body mass index values. Depending on serum uric acid levels, patients were divided into two groups: group 1 patients without hyperuricemia (n = 18) and group 2 patients with hyperuricemia (n = 16). Functional diagnostic methods were used: standard 12-channel electrocardiography, transtoral echocardiography, daily Holter monitoring. The main attention was paid to the study of the parameters of the left ventricle. Students t-test was used to determine the significance of the differences, the results at p 0.05 were considered reliable. It was established that adolescents with hyperuricemia were more often diagnosed with primary and secondary arterial hypertension, less often with labile arterial hypertension and autonomic dysfunction syndrome by hypertensive type, and adolescents without hyperuricemia were equally often diagnosed with primary arterial hypertension and labile arterial hypertension, autonomic dysfunction syndrome by hypertensive type. Signs of left ventricular remodeling according to echocardiography were more often noted in boys without hyperuricemia (62.5% of cases) than in girls without hyperuricemia (10%; p 0.01) and in boys with hyperuricemia (26.7%; p 0,05). The findings indicated more significant changes in the morphofunctional state of the cardiovascular system in adolescents with hypertensive conditions and manifestations of metabolic syndrome without hyperuricemia, which requires further study.

scholarly journals The abilities of losartan in angioprotection in hypertensive patients with hyperuricemia

2012 ◽  
Vol 9 (4) ◽  
pp. 16-21
Author(s):  
S V Nedogoda ◽  
A A Ledyaeva ◽  
E V Chumachok ◽  
V V Tsoma ◽  
A S Salasyuk
Keyword(s):  
Uric Acid ◽  
Arterial Hypertension ◽  
Conventional Therapy ◽  
Antihypertensive Drugs ◽  
Vascular Wall ◽  
Antihypertensive Activity ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Open Label ◽  
Losartan Group

Aim: to evaluate the ability of the angiotensin II receptor blocker losartan (Lorista, KPKA) to reduce the level of uric acid and to correct the parameters of vascular wall elasticity in patients with arterial hypertension, hyperuricemia, and gout. Subjects and methods. An open-label, randomized, controlled, parallel group comparative (losartan versus conventional therapy with other antihypertensive drugs for 24 weeks) trial enrolled 40 patients with arterial hypertension, hyperuricemia, and gout. Results. No significant differences were found between the groups of losartan (Lorista) and conventional therapy with other antihypertensive drugs groups in their antihypertensive activity. At the same time the losartan group showed a considerably more decrease in uric acid levels than did the conventional group (34,7% versus 7,8% in the group of therapy with other antihypertensive drugs (p

scholarly journals The relationship of risk factors and heart remodeling in patients with metabolic syndrome and arterial hypertension

2021 ◽  
pp. 19-25
Author(s):  
E. L. Polozova ◽  
E. V. Puzanova ◽  
A. A. Seskina ◽  
N. S. Nefedov
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Left Ventricular Hypertrophy ◽  
Arterial Hypertension ◽  
Cardiac Remodeling ◽  
Ventricular Hypertrophy ◽  
Metabolic Disorders ◽  
Clinical Analysis ◽  
Left Ventricular ◽  
Cardiology Department

Introduction. Arterial hypertension (AH) is a widespread disease in the population of the world. It also acts as one of the constituent components of metabolic syndrome (MS), which is a global “epidemic” of our time. Target organs in such patients are affected much earlier and their changes are more pronounced than in hypertensive patients without metabolic disorders. It is important to study the contribution of risk factors to the progression of cardiac dysfunction in this category of patients.Purpose of the study. To study the influence of risk factors on heart remodeling in patients with hypertension, burdened and not burdened by metabolic disorders, selected for clinical analysis from the cardiology department of the Republican Clinical Hospital № 4, Saransk in 2016-2019.Materials and methods. For clinical analysis, 139 patients were selected from the cardiology department of the Republican Clinical Hospital No. 4, Saransk. Depending on the presence of metabolic disorders, the following groups were identified: Group I (n = 72) – patients with MS and AH; Group II (n = 67) – AH patients without metabolic disorders. The study evaluated the morphological and functional state of the myocardium and risk factors in the analyzed groups.Results. In the group of patients with hypertension, aggravated by metabolic disorders, more pronounced processes of cardiac remodeling were revealed. It has been shown that patients with MS develop both eccentric and concentric models of left ventricular hypertrophy. The influence of the level of blood pressure and body mass index is differently reflected on the type of restructuring of the geometry of the myocardium. Patients with hypertension combined with metabolic disorders have a wider prevalence of risk factors. The burden of risk factors is higher in patients with concentric left ventricular hypertrophy and MS.Conclusions. The role of metabolic disorders in the mechanism of cardiac remodeling development in patients with hypertension in combination with MS was determined. 

scholarly journals Left ventricular diastolic dysfunction in patients with metabolic syndrome

2012 ◽  
Vol 65 (1-2) ◽  
pp. 18-22 ◽  
Author(s):  
Davor Penjaskovic ◽  
Dejan Sakac ◽  
Jovanka Dejanovic ◽  
Radovan Zec ◽  
Nada Zec-Petkovic ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Diastolic Dysfunction ◽  
Central Obesity ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Positive Correlation ◽  
Medical Disorders ◽  
Cardiovascular Morbidity And Mortality

Metabolic syndrome (MetS), which is a cluster of medical disorders, is common and it is associated with increased cardiovascular morbidity and mortality. The aim of this study was to evaluate the relationship between characteristics of metabolic syndrome and the grade of diastolic dysfunction. The study included 72 patients (29 male and 43 female), who had central obesity and at least two of the other four characteristics of metabolic syndrome according to IDF (International Diabetes Federation) criteria. The exclusion criteria were age above 65, impaired systolic function (left ventricular ejection fraction <55%), atrial fibrillation, valvular and pericardial heart disease. Diastolic function was determined according to the criteria of the American Society of Echocardiography. There was a positive correlation between the number of characteristics of metabolic syndrome and the diastolic dysfunction grade (p<0.0001). The positive correlation was found between the grade of diastolic dysfunction and the waist circumference (p<0.0001), arterial hypertension (p<0.001), pared glucose tolerance/diabetes (P=0.0063), and hypertriglyceridemia (p=0.0262). A low level of high-density lipoprotein did not show a statistically significant correlation. The presence of metabolic syndrome is associated with the presence of diastolic dysfunction. The grade of diastolic dysfunction is dependent on the number of coexisting characteristics of metabolic syndrome. Arterial hypertension, central obesity, hyperglycemia and hypertriglyceridemia showed a significant correlation with the degree of diastolic dysfunction.

scholarly journals Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension

2011 ◽  
Vol 10 (6) ◽  
pp. 24-29
Author(s):  
S. V. Nedogoda ◽  
E. V. Chumachok ◽  
A. A. Ledyaeva ◽  
V. V. Tsoma
Keyword(s):  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Standard Therapy ◽  
Therapy Group ◽  
Angiotensin Ii Receptor ◽  
Standard Therapy Group ◽  
Significant Difference ◽  
Losartan Group ◽  
Randomised Controlled

Aim. To assess the potential of the angiotensin II receptor antagonist losartan for the correction of hyperuricemia (HU) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. This open, randomised, controlled comparative study in parallel groups included 60 AH patients with MS and HU. The patients received losartan or standard therapy for 12 weeks. Results. Throughout the follow-up period, no significant difference in antihypertensive effect was observed between the losartan and standard therapy groups. Losartan group patients demonstrated a more pronounced decrease in uric acid levels (-34,7 % vs. -7,8 % in the standard therapy group; p<0,05). In addition, losartan therapy, compared to the standard treatment, was associated with improved vascular elasticity, as manifested by the pulse wave velocity decrease (-27,8 % vs. -8,1 % for carotid-femoral index, and -30,2 % vs. -12,6 % for carotidradial index, respectively; both p<0,05).

scholarly journals Modern opportunities for optimising the treatment of patients with coronary heart disease and arterial hypertension: role of zofenopril

2012 ◽  
Vol 11 (4) ◽  
pp. 85-92
Author(s):  
A. G. Evdokimova ◽  
V. V. Evdokimov ◽  
N. V. Leonenko ◽  
A. V. Smetanin
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Arterial Hypertension ◽  
Clinical Case ◽  
Ace Inhibitor ◽  
Cardiovascular Death ◽  
Left Ventricular ◽  
Antihypertensive Activity ◽  
Acute Mi

The wide prevalence (82%) of coronary heart disease (CHD) in combination with arterial hypertension (AH), as well as its initiating role in the development of fatal complications, such as myocardial infarction (MI) or heart failure, emphasise the need for the choice of optimal ACE inhibitors with organ-protective characteristics. This paper presents a literature review on the effectiveness of a SH-containing ACE inhibitor zofenopril in patients with CHD and AH, in terms of its anti-anginal and antihypertensive activity. The authors summarise the results of the international SMILE studies which included patients after acute MI. It was demonstrated that zofenopril therapy is associated with reduced combined incidence of cardiovascular death or cardiovascular hospitalisation, and is also safe in the acute post-MI period. In patients with preserved left ventricular function, zofenopril reduced the incidence of angina attacks and arrhythmias of coronary genesis, as well as improved exercise capacity. A clinical case of zofenopril therapy, as a part of a complex treatment regimen, is also presented.

scholarly journals Efficacy of irbesartan in arterial hypertension and metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 53-56
Author(s):  
O D Ostroumova ◽  
A A Zykova ◽  
T A Polosova ◽  
O V Bondarets
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Ii ◽  
Arterial Hypertension ◽  
Antihypertensive Drugs ◽  
Angiotensin Ii Receptor Blockers ◽  
Efficacy And Safety ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Receptor Blockers

The paper gives the data of Russian guidelines for the diagnosis and approaches to treating metabolic syndrome. It considers the choice of antihypertensive drugs in the treatment of hypertensive patients with metabolic syndrome. The benefits of angiotensin II receptor blockers are shown. The results of a number of trials evaluating the efficacy and safety of irbesartan used to manage arterial hypertension in metabolic syndrome are analyzed.

Sign in / Sign up

Export Citation Format

Share Document